Scientific deep-dive
Do You Lose Belly Fat on Semaglutide? What the Evidence Shows About Visceral Fat (2026)
Yes — semaglutide reduces total body fat and visceral (belly) fat. What DXA body-composition trials show about waist loss, muscle loss, and why you can't spot-reduce.
Yes — you do lose belly fat on semaglutide. Semaglutide (the active ingredient in Ozempic and Wegovy) drives loss of total body fat, and importantly it reduces visceral fat: the metabolically harmful fat packed around your abdominal organs that drives cardiometabolic risk. In a body-composition substudy of the SUSTAIN 8 trial that used DXA imaging, once-weekly semaglutide reduced total fat mass and visceral adipose tissue, and the proportion of fat in body mass fell while lean mass made up a larger share of what remained.[1] The pivotal STEP-1 obesity trial showed semaglutide 2.4 mg cut mean body weight by about 15% and waist circumference by roughly 13 cm versus placebo over 68 weeks — a direct, measurable shrinking of the midsection.[2] The honest nuances matter too: you cannot spot-reduce belly fat, some lean (muscle) mass comes off alongside the fat, and visceral-fat loss is a big part of why semaglutide improves blood pressure, lipids, and glucose. This is general information, not medical advice — your prescriber individualizes your care. See our Ozempic and Wegovy drug pages for the full profiles.
About this article
The body-composition claims below are anchored to a DXA-imaging substudy of the SUSTAIN 8 randomized controlled trial (McCrimmon et al., Diabetologia 2020), which measured total fat mass, lean body mass, and visceral adipose tissue directly rather than inferring them from the scale, and to the pivotal STEP-1 obesity trial (Wilding et al., NEJM 2021), which reported waist-circumference change as a co-measure of weight loss. The "labeled side effect" framing for the drug itself is consistent with the FDA prescribing information on DailyMed (NIH) for Ozempic and Wegovy (semaglutide). Reported magnitudes vary by trial population, dose, baseline body composition, and whether resistance training and protein intake were part of the program, so treat any specific figure as approximate and study-specific — not a personal prediction. For the muscle-loss side of the picture see our lean-mass guide, and for the broader profile see Ozempic side effects. This is general information, not medical advice — your prescriber manages your care.
Does semaglutide actually reduce belly fat?
Yes. The most rigorous evidence comes from body-composition substudies that image fat directly. In the SUSTAIN 8 body-composition substudy, adults with type 2 diabetes who took once-weekly semaglutide underwent DXA scanning that separated total fat mass, lean body mass, and visceral adipose tissue (VAT — the deep fat around the abdominal organs). Semaglutide reduced both total fat mass and visceral adipose tissue, and the percentage of total fat in the body fell while lean tissue made up a larger share of the lighter body that remained.[1] That is the key point: the weight you lose on semaglutide is predominantly fat, and the belly is one of the places that fat comes off.
The obesity trials reinforce this with a simpler, clinic-friendly measure: waist circumference. In STEP-1, semaglutide 2.4 mg once-weekly reduced mean body weight by about 14.9% versus 2.4% on placebo, and it reduced waist circumference by approximately 13.5 cm versus about 4.1 cm on placebo over 68 weeks.[2] A shrinking waistline is the most accessible real-world signal that abdominal fat — including the harmful visceral component — is coming down, which is why prescribers often track the tape measure alongside the scale.
Why you lose belly fat — and why you can't target it
Semaglutide does not have a "belly-fat" mechanism. It is a GLP-1 receptor agonist that reduces appetite and energy intake, which puts the body into an energy deficit. In that deficit the body draws on fat stores throughout the body — you lose belly fat because you are losing fat everywhere. There is no drug, food, exercise, or supplement that selectively removes fat from one region: spot-reduction is a myth, and semaglutide is no exception.
The encouraging wrinkle is that visceral fat tends to be mobilized readily and relatively early in weight loss. Visceral adipose tissue is metabolically active and lipolytically responsive, so it often comes off in good proportion as total fat mass falls — which is exactly the pattern the DXA substudy captured when it showed reductions in both total fat and the visceral compartment.[1] So while you cannot aim the fat loss at your abdomen, the abdomen is frequently one of the first beneficiaries.
The honest caveat: you lose some muscle too
Any meaningful weight loss — from semaglutide, surgery, or diet alone — removes some lean (muscle) mass along with the fat. Across weight-loss interventions, lean tissue commonly accounts for roughly a quarter to two-fifths of the total weight lost, with the exact split depending on the deficit, protein intake, baseline body composition, and how much resistance training is in the picture. The DXA substudy is reassuring on the direction — semaglutide lowered the percentage of fat and left lean tissue as a larger share of the body — but it does not mean zero muscle is lost.[1] Preserving lean mass is something you actively influence: adequate protein and resistance (strength) training are the two levers that shift the fat-to-lean ratio of your weight loss in your favor. We cover this in depth in our semaglutide and muscle / lean-mass loss guide.
Magnitude comparison
Illustrative pattern of body-composition change on semaglutide — fat mass falls the most, visceral (belly) fat falls substantially, and a smaller amount of lean mass is lost. Shown as percentage of total weight lost that comes from each compartment; this is a schematic of the typical direction reported in DXA body-composition substudies (SUSTAIN 8), not exact per-patient values, which vary with diet, protein, and resistance training.[[cite:1]][1]
- Total fat mass (the bulk of weight lost)70 % of weight lost
- …of which visceral (belly) fat is a notable share30 % of weight lost
- Lean (muscle) mass — protect with protein + resistance training30 % of weight lost
How to read this chart. The figures are illustrative of the direction and rough proportions seen in body-composition substudies — most of the weight lost on semaglutide is fat, a meaningful slice of that fat is visceral, and a smaller fraction is lean mass. They are not a measured outcome from any single patient or a guaranteed split. The "fat" and "visceral" bars overlap (visceral fat is part of total fat mass), so they are not meant to sum to 100%. Your own ratio depends heavily on protein intake and whether you strength-train.
Why visceral-fat loss is the cardiometabolic prize
Losing belly fat on semaglutide is not just cosmetic. Visceral adipose tissue is the metabolically dangerous fat — it sits around the liver, pancreas, and intestines, releases inflammatory signals and free fatty acids into the portal circulation, and is tightly linked to insulin resistance, high blood pressure, abnormal lipids, and fatty liver disease (MASLD, formerly NAFLD). Reducing the visceral compartment is a major reason semaglutide improves these markers, and the SUSTAIN 8 substudy's finding that semaglutide lowers VAT is mechanistically consistent with the blood-sugar, blood-pressure, and lipid improvements seen across the semaglutide trial program.[1][2] In other words, the shrinking waistline is a visible proxy for an invisible, clinically important shift in where your fat used to be.
One cosmetic flip side is worth naming honestly: because the fat loss is generalized, some people also lose subcutaneous facial fat — the "Ozempic face" effect. It is not a separate side effect so much as the same whole-body fat loss showing up in the cheeks and temples; it tends to be more noticeable with faster or larger weight loss. See Ozempic side effects for the broader picture.
How long until you lose belly fat — and how to measure it
Belly-fat loss on semaglutide is a weeks-to-months process, not days. Semaglutide is titrated upward in steps, and the appetite reduction — and the fat loss that follows — builds as the dose climbs and as the energy deficit accumulates. The STEP-1 and SUSTAIN 8 results reflect months of treatment (68 weeks and through end of trial, respectively), so set expectations on that horizon rather than expecting a flat stomach in a few weeks.[1][2] Practical guidance:
- Measure your waist, not just the scale. A tape measure at the navel captures abdominal-fat change that body weight alone can miss — especially if you are preserving or building muscle while losing fat. STEP-1 tracked waist circumference for exactly this reason.[2]
- Prioritize protein. Adequate daily protein is the single biggest dietary lever for keeping lean mass while you lose fat, which improves the fat-to-lean ratio of your weight loss.
- Add resistance training. Strength training signals the body to retain muscle during an energy deficit, helping ensure more of the weight you lose is fat — including visceral fat. See our muscle-loss guide for specifics.
- Stay hydrated and don't crash-diet. Aggressive under-eating on top of semaglutide's appetite suppression increases lean-mass loss and side effects without speeding fat loss in a healthy way.
- Be patient through titration. The largest body-composition changes in the trials accrued over many months at the higher maintenance doses, not in the first few low-dose weeks.[2]
Ready to start? Top vetted semaglutide providers
If you and a licensed prescriber decide semaglutide is appropriate for you, these are the vetted telehealth providers in our directory that offer compounded semaglutide, ranked by our editorial score. No insurance is required, and our editors verify each listing. For the lowest-cost legitimate options across every channel, see our cheapest GLP-1 without insurance buyer's guide.
Ready to start? Top vetted semaglutide providers by editorial score
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
No insurance needed · HSA/FSA eligible · vetted by our editors
Breeze Meds
Compounded GLP-1 access with named prescribers and 4-pharmacy network
Starting price: $199/mo
Get started →Read review Breeze Meds →RNK Health
Compounded GLP-1 alongside NAD+, peptide and longevity add-ons
Starting price: $197/mo
Get started →Read review RNK Health →Wellorithm
Compounded GLP-1 access with oral tablet options across 49 states
Starting price: $247/mo
Get started →Read review Wellorithm →SkinnyRx
Mainstream telehealth GLP-1 access
Starting price: $149.25/mo
Get started →Read review SkinnyRx →| Provider | Starting price | |
|---|---|---|
7.4Breeze Meds | $199/mo | Get started → |
8.1GobyMeds | $169/mo | Get started → |
7.6RNK Health | $197/mo | Get started → |
6.2Wellorithm | $247/mo | Get started → |
7.6SkinnyRx | $149.25/mo | Get started → |
Bottom line
- Yes — you lose belly fat on semaglutide. It drives loss of total body fat and reduces visceral (belly) fat, the metabolically harmful fat around the abdominal organs, per a DXA body-composition substudy of SUSTAIN 8.[1]
- In STEP-1, semaglutide 2.4 mg cut mean body weight by about 15% and waist circumference by roughly 13 cm versus placebo over 68 weeks — a measurable shrinking of the midsection.[2]
- You cannot spot-reduce. You lose belly fat because you lose fat throughout the body; visceral fat just tends to be mobilized readily and relatively early.
- Some lean (muscle) mass comes off too. Protect it with adequate protein and resistance training to improve the fat-to-lean ratio of your weight loss — see our muscle-loss guide.
- Visceral-fat loss is a major reason semaglutide improves blood pressure, lipids, glucose, and liver fat — the shrinking waist is a proxy for a real cardiometabolic shift.
- Belly-fat loss takes weeks to months; measure your waist, not just the scale, and be patient through dose titration.
- This is general information, not medical advice. Talk to a licensed prescriber. For access options see our best semaglutide providers and the cheapest GLP-1 without insurance guide.
Frequently asked questions
Frequently Asked Questions
References
- 1.McCrimmon RJ, Catarig AM, Frias JP, Lausvig NL, le Roux CW, Thielke D, Lingvay I. Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. DXA imaging measured total fat mass, lean body mass, and visceral adipose tissue; once-weekly semaglutide reduced total fat mass and visceral adipose tissue, and the percentage of total fat in body mass fell while lean mass made up a larger share of the lighter body. This is the primary direct-imaging evidence cited throughout the article that semaglutide reduces visceral (belly) fat and that most of the weight lost is fat. Diabetologia. 2020. PMID: 31897524.
- 2.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. STEP-1. Semaglutide 2.4 mg subcutaneous once-weekly produced a mean body-weight reduction of approximately 14.9% versus 2.4% on placebo at week 68, and reduced waist circumference by approximately 13.5 cm versus approximately 4.1 cm on placebo. The waist-circumference outcome is cited as the clinic-friendly, measurable signal of abdominal-fat reduction. N Engl J Med. 2021. PMID: 33567185.
- 3.U.S. Food and Drug Administration (DailyMed, NIH). Ozempic (semaglutide) injection prescribing information. FDA-approved label for semaglutide for type 2 diabetes, including mechanism (GLP-1 receptor agonism reducing appetite and energy intake), the Adverse Reactions section, and the cardiometabolic effects of the molecule. Used to confirm semaglutide's identity, mechanism, and labeled-effect framing. DailyMed (U.S. National Library of Medicine). 2026. https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=ozempic+semaglutide
- 4.U.S. Food and Drug Administration (DailyMed, NIH). Wegovy (semaglutide) injection prescribing information. FDA-approved label for semaglutide 2.4 mg for chronic weight management, including the Indications, Adverse Reactions, and Warnings and Precautions sections. Used to confirm the weight-management indication and labeling for the same molecule discussed throughout the article. DailyMed (U.S. National Library of Medicine). 2026. https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=wegovy+semaglutide
Related research
Cortisol Belly Fat on a GLP-1: Honest Evidence Review
Cushing's syndrome is real but rare (~2-3/million/yr). Subclinical chronic stress modestly elevates cortisol, but the dominant pathway to visceral fat is indirect — reward-driven overeating and sleep loss. Supplements lack RCT support.
12 min read
Ozempic and Muscle Loss: How Much Lean Mass You Lose & How to Protect It (2026)
Some weight lost on Ozempic is muscle — roughly 25 to 40% of total loss can be lean mass, like any rapid weight loss. How much you actually lose, why muscle matters, who is most at risk, and the evidence-based ways to protect it: adequate protein, resistance training, and a sensible rate of loss.
8 min read
Ozempic Legs: Loose Skin, Muscle Loss, and Leg Changes Explained
What 'Ozempic legs' actually are — subcutaneous fat loss, lean-mass reduction, and loose/saggy skin that make legs look thinner, older, hollow, or veiny after GLP-1 weight loss — who's most at risk, and how to prevent and manage it.
9 min read
Ozempic Feet and Legs: Fat-Pad Thinning, Leg Changes, and When to Worry
Ozempic feet and legs explained: plantar fat-pad thinning, leg muscle and fat loss after GLP-1 weight loss, what helps, and the red flags that need a doctor.
10 min read
Mounjaro and Muscle Loss: How Much Lean Mass You Lose & How to Protect It (2026)
Does Mounjaro (tirzepatide) cause muscle loss? About 25 to 40% of weight lost on a GLP-1/GIP can be lean mass, but it is largely preventable. How much you lose, why it matters, and how to protect muscle with protein and resistance training — verified against the SURMOUNT trials.
8 min read
Mounjaro Butt: Why Tirzepatide Deflates the Buttocks, and How to Avoid and Fix It
Mounjaro butt is the deflated, flattened backside after rapid tirzepatide weight loss. Why it happens, why it can beat Ozempic butt, and how to avoid and fix it.
9 min read
Where to get semaglutide (Ozempic / Wegovy) safely: vetted online providers
Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.
No insurance needed · vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Gala
Compounded GLP-1/GIP combo therapy on a yearly subscription with free shipping nationwide
From $179/mo
Get started →TMates
Nationwide compounded GLP-1 availability including Puerto Rico
From $249/mo
Get started →Trimi Health
Budget-conscious shoppers
From $99/mo
Get started →